<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001034</url>
  </required_header>
  <id_info>
    <org_study_id>CPCRA 023</org_study_id>
    <secondary_id>11573</secondary_id>
    <nct_id>NCT00001034</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV</brief_title>
  <official_title>A Randomized, Comparative, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of Cytomegalovirus (CMV) Retinal and Gastrointestinal Mucosal Disease in HIV-Infected Individuals With Severe Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of oral ganciclovir for prophylaxis against
      cytomegalovirus (CMV) retinal and gastrointestinal mucosal disease in HIV-infected patients
      with severe immunosuppression.

      The most recent treatments against CMV disease have been ganciclovir and foscarnet. Until
      recently, both drugs required intravenous administration. An oral form of ganciclovir, if
      shown to be effective therapy against CMV, would be a more suitable method of administration
      for prophylaxis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most recent treatments against CMV disease have been ganciclovir and foscarnet. Until
      recently, both drugs required intravenous administration. An oral form of ganciclovir, if
      shown to be effective therapy against CMV, would be a more suitable method of administration
      for prophylaxis.

      Patients are randomized in a 2:1 ratio to receive either oral ganciclovir or placebo for a
      minimum of 12 months. PER AMENDMENT 9/19/94: Patients who have not reached a study endpoint
      may choose to continue blinded prophylaxis or discontinue blinded prophylaxis and begin
      open-label ganciclovir. PER AMENDMENT 5/2/95: After the common closing date (6/3/95) patients
      who have not met a CMV end point or experienced a serious toxicity that required permanent
      discontinuation of active oral ganciclovir will be eligible to receive open-label oral
      ganciclovir through an open-label extension phase of study 023 until 8/31/95.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">August 1995</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>850</enrollment>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <condition>Gastrointestinal Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Antiretroviral therapy.

          -  Anti-PCP prophylaxis.

          -  Maintenance or prophylaxis therapy for other opportunistic infections besides CMV.

        Patients must have:

          -  Working diagnosis of HIV infection.

          -  CD4 count &lt;= 100 cells/mm3.

          -  Positive CMV serology (IgG) or CMV culture, in the absence of active disease,
             documented at any time prior to study entry.

          -  Reasonably good health.

          -  Life expectancy of at least 6 months.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Acute life-threatening illness.

          -  Active lymphoma.

          -  Hypersensitivity to acyclovir.

          -  Lack of willingness or ability, in the opinion of the clinician, to comply with
             protocol requirements.

        Concurrent Medication:

        Excluded:

          -  Vidarabine.

          -  Amantadine hydrochloride (Symmetrel).

          -  CMV hyperimmune globulin/intravenous immune globulin.

          -  Cytarabine.

          -  Fiacitabine (FIAC) or fialuridine (FIAU).

          -  Foscarnet.

          -  Intravenous ganciclovir.

          -  HPMPC.

          -  Idoxuridine.

          -  Intravenous acyclovir.

          -  Oral acyclovir at &gt; 1 g/day.

          -  Other drugs with potential anti-CMV activity.

        Prior Medication:

        Excluded within 60 days prior to study entry:

          -  Foscarnet.

        Excluded within 2 weeks prior to study entry:

          -  Vidarabine.

          -  Amantadine hydrochloride (Symmetrel).

          -  CMV hyperimmune globulin/intravenous immune globulin.

          -  Cytarabine.

          -  Fiacitabine (FIAC) or fialuridine (FIAU).

          -  Ganciclovir.

          -  HPMPC.

          -  Idoxuridine.

          -  Intravenous acyclovir.

          -  Oral acyclovir at &gt; 1 g/day.

          -  Other drugs with potential anti-CMV activity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brosgart C</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Craig C</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Community Consortium of San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver CPCRA / Denver Public Hlth</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Hosp / Med Ctr of Delaware</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19899</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Med Ctr / Regional AIDS Program</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Alliance - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Comm AIDS Rsch Prog / Tulane Univ Med</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive AIDS Alliance of Detroit</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hosp</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schering - Plough Corp</name>
      <address>
        <city>Kenilworth</city>
        <state>New Jersey</state>
        <zip>07033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Jersey Community Research Initiative</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Lebanon Hosp Ctr</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addiction Research and Treatment Corp</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Directors Network of Region II</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem AIDS Treatment Group / Harlem Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland Veterans Adm Med Ctr / Rsch &amp; Education Grp</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond AIDS Consortium</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brosgart C, Craig C, Louis TA, Hillman D, Costanzo L, Timpone J, Scott J, Nunley F, Stempien MJ. Design and demographics in a multicenter trial of cytomegalovirus (CMV) prophylaxis in advanced HIV disease. Int Conf AIDS. 1994 Aug 7-12;10(2):10 (abstract no 331B)</citation>
  </reference>
  <reference>
    <citation>Brosgart CL, Louis TA, Hillman DW, Craig CP, Alston B, Fisher E, Abrams DI, Luskin-Hawk RL, Sampson JH, Ward DJ, Thompson MA, Torres RA. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 1998 Feb 12;12(3):269-77.</citation>
    <PMID>9517989</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>September 28, 2013</last_update_submitted>
  <last_update_submitted_qc>September 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinitis</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Gastrointestinal System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

